Stock Market

Turnstone Biologics sets terms for proposed $75 million IPO (Pending:TSBX)

Andrey Tolkachev

Oncology drug developer Turnstone Biologics (TSBX) has set the terms for its proposed $75 million initial public offering.

Turning stone said in the filing that it wants to offer 5.8 million shares for between $12 and $14, which would increase by about $75 million if priced at the midpoint. The underwriters will receive a 30-day option to buy up to 870k additional shares at the IPO price to cover the over-allotment.

IPO Update: Turnstone Biologics Prepares $75 Million IPO Plans Turnstone Biologics Begins $86 Million US IPO Plans

Related Articles

Back to top button